GlassScriptPhysician profile
Syed Hammad Shabbir
NPI 1669868485
$3,683.83
in general payments reported to CMS, 2019-2025
29 companies · $996 in 2025
The $996 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $48.12 · 2021: $288 · 2022: $925 · 2023: $660 · 2024: $767 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $936.07 | 2020-2025 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $754.05 | 2021-2025 | Ubrelvy, Qulipta |
| Eisai INC. | $253.01 | 2022-2025 | |
| Genentech USA, INC. | $190.17 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Lilly USA, LLC | $179.16 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $145.35 | 2022-2024 | Briviact |
| Novartis Pharmaceuticals Corporation | $111.54 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $109.62 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $95.49 | 2021-2022 | |
| Sk Life Science, INC. | $86.54 | 2022-2025 | |
| Horizon Therapeutics Plc | $85.79 | 2022-2023 | Uplizna, Tepezza |
| Amgen INC. | $80.23 | 2023-2025 | Uplizna, Aimovig |
| Banner Life Sciences, LLC | $75.88 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $65.02 | 2021-2023 | Ponvory |
| Argenx US, INC. | $64.71 | 2022-2023 | Vyvgart |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $56.18 | 2022-2024 | |
| Tanabe Pharma America, INC. | $51.39 | 2025 | Radicava |
| Emd Serono, INC. | $48.67 | 2025 | |
| Genzyme Corporation | $44.09 | 2025 | |
| Livanova USA, INC. | $42.85 | 2022 | |
| Acadia Pharmaceuticals INC | $40.80 | 2022-2025 | Nuplazid |
| Neurelis, INC. | $30.39 | 2020-2021 | |
| Celgene Corporation | $28.55 | 2021-2022 | |
| Tg Therapeutics, INC. | $24.38 | 2025 | |
| Lundbeck LLC | $23.48 | 2022 | |
| Pfizer INC. | $21.17 | 2025 | |
| Acorda Therapeutics, INC | $15.75 | 2023 | Ampyra, Inbrija |
| Avion Pharmaceuticals | $15.52 | 2022 | |
| Sumitomo Pharma America, INC. | $7.98 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Shabbir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.